A carregar...
Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States
BACKGROUND: Dalfampridine extended release tablets (dalfampridine-ER; prolonged-, modified, or sustained-release fampridine outside the US), 10 mg twice daily, was approved by the US Food and Drug Administration (FDA) in January 2010 to improve walking in people with multiple sclerosis, as determine...
Na minha lista:
| Publicado no: | Drug Healthc Patient Saf |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4687626/ https://ncbi.nlm.nih.gov/pubmed/26719727 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DHPS.S97113 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|